Phase III Randomised Trial to Evaluate the Benefit of Adjuvant Hormonal Treatment With Leuprorelin Acetate (Eligard, 45 mg) for 24 Months After Radical Prostatectomy in Patients With High Risk of Recurrence.
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 20 Jun 2016 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2018.
- 20 Jun 2016 Status changed from active, no longer recruiting to recruiting.
- 02 Oct 2011 New trial record